Nivolumab
Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
Exelixismonoclonal_antibodyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
23 Active assets in the Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus Peking University First Hospital | Phase 2 | BB |
Axitinib University of California, San Francisco | Phase 3 | B |
gw786034 Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Phase 2 | B |
MODIFIED VACCINIA VIRUS ANKARA-5T4 ANTIGEN Oxford BioMedica | Phase 3 | B |
Toripalimab RenJi Hospital | Phase 2 | B |
View all 39 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →